000

NEOPHARM

No trades
See on Supercharts
Market capitalization
‪201.77 B‬KRW
‪23.21 B‬KRW
‪97.10 B‬KRW
‪4.46 M‬
Beta (1Y)
−0.18

About NEOPHARM

CEO
Yang-Soo Kim
Headquarters
Daejeon
Employees (FY)
153
Founded
2000
ISIN
KR7092730001
FIGI
BBG000QLSRQ6
NeoPharm Co., Ltd. engages in the development, manufacture, and sale of cosmetics, medical, and health products. Its products include emulsified and functional skin care products for sensitive and dry skin, treatment of atopic dermatitis and psoriasis, and therapy for steroid side effects. The company was founded on July 1, 2000 and is headquartered in Daejeon, South Korea.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of 092730 is 25750 KRW — it has decreased by 0.19% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on KRX exchange NEOPHARM stocks are traded under the ticker 092730.
092730 stock is 2.35% volatile and has beta coefficient of −0.18. Check out the list of the most volatile stocks — is NEOPHARM there?
NEOPHARM revenue for the last quarter amounts to ‪24.20 B‬ KRW despite the estimated figure of ‪25.70 B‬ KRW. In the next quarter revenue is expected to reach ‪26.70 B‬ KRW.
Yes, you can track NEOPHARM financials in yearly and quarterly reports right on TradingView.
092730 stock has risen by 9.57% compared to the previous week, the month change is a 8.42% rise, over the last year NEOPHARM has showed a 43.77% increase.
092730 net income for the last quarter is ‪6.00 B‬ KRW, while the quarter before that showed ‪4.93 B‬ KRW of net income which accounts for 21.75% change. Track more NEOPHARM financial stats to get the full picture.
Today NEOPHARM has the market capitalization of ‪201.77 B‬, it has increased by 4.20% over the last week.
Yes, 092730 dividends are paid annually. The last dividend per share was 750.00 KRW. As of today, Dividend Yield (TTM)% is 2.91%. Tracking NEOPHARM dividends might help you take more informed decisions.
NEOPHARM dividend yield was 2.90% in 2023, and payout ratio reached 25.27%. The year before the numbers were 3.65% and 32.15% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, 092730 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NEOPHARM stock right from TradingView charts — choose your broker and connect to your account.
092730 reached its all-time high on Apr 11, 2018 with the price of 63300 KRW, and its all-time low was 2200 KRW and was reached on Oct 23, 2008.
See other stocks reaching their highest and lowest prices.
As of Apr 26, 2024, the company has 153.00 employees. See our rating of the largest employees — is NEOPHARM on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NEOPHARM technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NEOPHARM stock shows the buy signal. See more of NEOPHARM technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NEOPHARM EBITDA is ‪26.93 B‬ KRW, and current EBITDA margin is 27.73%. See more stats in NEOPHARM financial statements.